Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257192 · ClinicalTrials.gov registry record · Phase 3
Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Terminated
- Registry status
- Phase 3
- Development phase
- 284
- Enrollment target
NCT00257192 is a Phase 3 study that was terminated before completion, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 284 participants.
The verdict
NCT00257192, a Phase 3 study, was terminated before completion, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 284 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of adolescents (ages 13-17) with schizophrenia
Interventions
- DRUG placebo
- DRUG Ziprasidone oral capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00257192
The ClinicalTrials.gov registry entry for NCT00257192 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 284 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00257192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00257192 about?
NCT00257192 is a clinical study titled "Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia". The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of adolescents (ages 13-17) with schizophrenia
What is the current status of trial NCT00257192?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 284 participants. The study started on 2006-04. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00257192?
The interventions under investigation include: placebo (DRUG), Ziprasidone oral capsules (DRUG).
Who is sponsoring clinical trial NCT00257192?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.